SOLARA ACTIVE PHARMA [SOLARAPP1] vs Sun Pharmaceutical [SUNPHARMA] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: SOLARA ACTIVE PHARMA SCIENCES wins in 5 metrics, Sun Pharmaceutical Industries Ltd. wins in 14 metrics, with 0 ties. Sun Pharmaceutical Industries Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | SOLARA ACTIVE PHARMA SCIENCES | Sun Pharmaceutical Industries Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 300.92 | 36.73 | Sun Pharmaceutical Industries Ltd. |
| Price-to-Book Ratio | 1.05 | 5.15 | SOLARA ACTIVE PHARMA SCIENCES |
| Debt-to-Equity Ratio | 51.38 | 6.68 | Sun Pharmaceutical Industries Ltd. |
| PEG Ratio | -1.02 | 3.59 | Sun Pharmaceutical Industries Ltd. |
| EV/EBITDA | 11.85 | 23.61 | SOLARA ACTIVE PHARMA SCIENCES |
| Profit Margin (TTM) | -1.52% | 19.21% | Sun Pharmaceutical Industries Ltd. |
| Operating Margin (TTM) | 3.37% | 26.17% | Sun Pharmaceutical Industries Ltd. |
| EBITDA Margin (TTM) | 3.37% | 26.17% | Sun Pharmaceutical Industries Ltd. |
| Return on Equity | 0.05% | 15.08% | Sun Pharmaceutical Industries Ltd. |
| Return on Assets (TTM) | 0.02% | 11.87% | Sun Pharmaceutical Industries Ltd. |
| Free Cash Flow (TTM) | $1.73B | $119.44B | Sun Pharmaceutical Industries Ltd. |
| Dividend Yield | N/A | 0.97% | N/A |
| 1-Year Return | 13.08% | 7.25% | SOLARA ACTIVE PHARMA SCIENCES |
| Price-to-Sales Ratio (TTM) | 1.66 | 7.05 | SOLARA ACTIVE PHARMA SCIENCES |
| Enterprise Value | $19.97B | $3,783.37B | Sun Pharmaceutical Industries Ltd. |
| EV/Revenue Ratio | 1.59 | 6.66 | SOLARA ACTIVE PHARMA SCIENCES |
| Gross Profit Margin (TTM) | 46.53% | 80.96% | Sun Pharmaceutical Industries Ltd. |
| Revenue per Share (TTM) | $231 | $237 | Sun Pharmaceutical Industries Ltd. |
| Earnings per Share (Diluted) | $-4.82 | $45.46 | Sun Pharmaceutical Industries Ltd. |
| Beta (Stock Volatility) | 0.84 | 0.11 | Sun Pharmaceutical Industries Ltd. |
SOLARA ACTIVE PHARMA SCIENCES vs Sun Pharmaceutical Industries Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| SOLARA ACTIVE PHARMA SCIENCES | 12.87% | 2.56% | 2.47% | -20.88% | -31.50% | -20.88% |
| Sun Pharmaceutical Industries Ltd. | -0.47% | -3.03% | -1.92% | 2.17% | -1.01% | 3.92% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| SOLARA ACTIVE PHARMA SCIENCES | 13.08% | 31.31% | 31.31% | 31.31% | 31.31% | 31.31% |
| Sun Pharmaceutical Industries Ltd. | 7.25% | 79.99% | 166.96% | 144.01% | 669.48% | 2,278.32% |
Performance & Financial Health Analysis: SOLARA ACTIVE PHARMA SCIENCES vs Sun Pharmaceutical Industries Ltd.
| Metric | SOLARAPP1 | SUNPHARMA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹20.78B | ₹3.88T |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 238 | 3,903,142 |
| 90 Day Avg. Volume | 704 | 3,253,866 |
| Last Close | ₹308.70 | ₹1,780.10 |
| 52 Week Range | ₹247.95 - ₹511.00 | ₹1,548.00 - ₹1,916.60 |
| % from 52W High | -39.59% | -7.12% |
| All-Time High | ₹511.00 (Aug 29, 2025) | ₹1,960.35 (Sep 30, 2024) |
| % from All-Time High | -39.59% | -9.19% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.16% | 0.14% |
| Quarterly Earnings Growth | 0.16% | 0.16% |
| Financial Health | ||
| Profit Margin (TTM) | -0.02% | 0.19% |
| Operating Margin (TTM) | 0.03% | 0.26% |
| Return on Equity (TTM) | 0.00% | 0.15% |
| Debt to Equity (MRQ) | 51.38 | 6.68 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹293.20 | ₹324.46 |
| Cash per Share (MRQ) | ₹0.88 | ₹115.87 |
| Operating Cash Flow (TTM) | ₹1.70B | ₹110.84B |
| Levered Free Cash Flow (TTM) | ₹5.40M | ₹109.29B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.97% |
| Last 12-Month Dividend | N/A | ₹16.50 |
Valuation & Enterprise Metrics Analysis: SOLARA ACTIVE PHARMA SCIENCES vs Sun Pharmaceutical Industries Ltd.
| Metric | SOLARAPP1 (Apr 08, 2026) | SUNPHARMA (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 300.92 | 36.73 |
| Forward P/E | N/A | 29.48 |
| PEG Ratio | -1.02 | 3.59 |
| Price to Sales (TTM) | 1.66 | 7.05 |
| Price to Book (MRQ) | 1.05 | 5.15 |
| Market Capitalization | ||
| Market Capitalization | ₹20.78B | ₹3.88T |
| Enterprise Value | ₹19.97B | ₹3.78T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.59 | 6.66 |
| Enterprise to EBITDA | 11.85 | 23.61 |
| Risk & Other Metrics | ||
| Beta | 0.84 | 0.11 |
| Book Value per Share (MRQ) | ₹293.20 | ₹324.46 |
Financial Statements Comparison: SOLARA ACTIVE PHARMA SCIENCES vs Sun Pharmaceutical Industries Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | SOLARAPP1 (2025) | SUNPHARMA (2025) |
|---|---|---|
| Revenue/Sales | 12.41B | 520.41B |
| Cost of Goods Sold | 6.46B | 121.98B |
| COGS % of Revenue | 52.0% | 23.4% |
| Gross Profit | 5.96B | 398.44B |
| Gross Margin | 48.0% | 76.6% |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | 1.11B | 125.81B |
| Operating Margin | 9.0% | 24.2% |
| EBITDA | 2.05B | 167.25B |
| EBITDA Margin | 16.5% | 32.1% |
| Pre-Tax Income | 5.40M | 137.52B |
| Pre-Tax Income % of Revenue | 0.0% | 26.4% |
| Income Tax | 0 | 27.72B |
| Income Tax % of Revenue | 0.0% | 5.3% |
| Net Income (Profit) | 5.40M | 109.65B |
| Profit Margin | 0.0% | 21.1% |
Balance Sheet & Liquidity Metrics
| Metric | SOLARAPP1 (2025) | SUNPHARMA (2025) |
|---|---|---|
| Cash & Equivalents | 39.50M | 102.69B |
| Total Current Assets | 7.29B | 526.24B |
| Total Current Assets % of Revenue | 58.7% | 101.1% |
| Total Current Liabilities | 9.44B | 181.94B |
| Total Current Liabilities % of Revenue | 76.0% | 35.0% |
| Long-Term Debt | 1.32B | 3.58B |
| Long-Term Debt % of Revenue | 10.6% | 0.7% |
| Total Shareholders Equity | 10.97B | 724.86B |
| Retained Earnings | -3.16B | 578.62B |
| Retained Earnings % of Revenue | -25.4% | 111.2% |
| Property, Plant & Equipment | 7.96B | 100.36B |
Cash Flow Statement Comparison
| Metric | SOLARAPP1 (2025) | SUNPHARMA (2025) |
|---|---|---|
| Operating Cash Flow | 1.70B | 110.84B |
| Operating Cash Flow % of Revenue | 13.7% | 21.3% |
| Capital Expenditures | 3.80M | -20.68B |
| Free Cash Flow | 1.73B | 119.44B |
| FCF Margin | 13.9% | 23.0% |
| Debt Repayment | -1.11B | -43.44B |
| Common Stock Repurchase | N/A | -29.00B |
Short Interest & Institutional Ownership Analysis
| Metric | SOLARAPP1 | SUNPHARMA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 12.00M | 2.40B |
| Float Shares | 30.10M | 1.07B |
| % Held by Insiders | 0.00% | 55.62% |
| % Held by Institutions | 4.45% | 28.69% |
| % Held by Public | 95.55% | 15.69% |
Dividend Analysis & Yield Comparison: SOLARA ACTIVE PHARMA SCIENCES vs Sun Pharmaceutical Industries Ltd.
| Metric | SOLARAPP1 | SUNPHARMA |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹16.50 |
| Last 12-Month Dividend Yield | N/A | 0.97% |
| 3-Year Avg Annual Dividend | N/A | ₹17.33 |
| 3-Year Avg Dividend Yield | N/A | 0.51% |
| 3-Year Total Dividends | N/A | ₹52.00 |
| Ex-Dividend Date | N/A | Feb 05, 2026 |